BioCentury
ARTICLE | Clinical News

Norastemizole: Filed an IND with the FDA to begin a series of fast-track Phase II trials

January 15, 1996 8:00 AM UTC

Sepracor Inc. (SEPR), Marlborough, Mass. Product: Norastemizole, active metabolite of Janssen's Hismanal (astemizole) antihistamine Indication: Allergy Status: Filed an IND with the FDA to begin a ser...